Last reviewed · How we verify

Measles and Rubella (MR) — Competitive Intelligence Brief

Measles and Rubella (MR) (Measles and Rubella (MR)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Measles virus and Rubella virus antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Measles and Rubella (MR) (Measles and Rubella (MR)) — International Centre for Diarrhoeal Disease Research, Bangladesh. The MR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles and rubella viruses through live attenuated viral antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Measles and Rubella (MR) TARGET Measles and Rubella (MR) International Centre for Diarrhoeal Disease Research, Bangladesh phase 3 Live attenuated vaccine Measles virus and Rubella virus antigens
Bacille Calmette Guerin (BCG) Bacille Calmette Guerin (BCG) Bandim Health Project marketed Live attenuated vaccine
Pentavalent rotavirus vaccine Pentavalent rotavirus vaccine Sanofi Pasteur, a Sanofi Company marketed Live attenuated vaccine
Rotavirus Vaccine (ROTARIX) Rotavirus Vaccine (ROTARIX) International Centre for Diarrhoeal Disease Research, Bangladesh marketed Live attenuated vaccine
Attenuated Hepatitis A Vaccine, H2 Strain Attenuated Hepatitis A Vaccine, H2 Strain Jiangsu Province Centers for Disease Control and Prevention marketed Live attenuated vaccine Hepatitis A virus
Varicella Virus Vaccine Live Varicella Virus Vaccine Live Sanofi Pasteur, a Sanofi Company marketed Live attenuated vaccine Varicella-zoster virus (VZV)
Yellow fever vaccine, Institut Pasteur Yellow fever vaccine, Institut Pasteur University of Oxford marketed Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

  1. GlaxoSmithKline · 19 drugs in this class
  2. Merck Sharp & Dohme LLC · 11 drugs in this class
  3. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
  4. PATH · 5 drugs in this class
  5. Sanofi · 5 drugs in this class
  6. Bandim Health Project · 5 drugs in this class
  7. Centers for Disease Control and Prevention · 3 drugs in this class
  8. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
  9. Beijing Center for Disease Control and Prevention · 2 drugs in this class
  10. Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Measles and Rubella (MR) — Competitive Intelligence Brief. https://druglandscape.com/ci/measles-and-rubella-mr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: